3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
4
Prostatic Neoplasms
3
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumour
1
Recurrence
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
1
Healthy Participants
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumours
1
Advanced Solid Malignancy,
1
Advanced Solid Malignancy
1
Advanced Gastric Cancer
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
adavosertib
3
Paclitaxel
3
olaparib
2
durvalumab
2
Fluorouracil
2
Carboplatin
2
danvatirsen
1
capivasertib
1
Pantoprazole
1
Leucovorin
1
Irinotecan
1
Injections
1
Gemcitabine
1
Doxorubicin
1
Cisplatin
1
AZD0156
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Solid Tumours
×
capivasertib
×
Clear all
NCT04742036
2022-08-19
Capivasertib China PK Study
AstraZeneca
Phase 1
Completed
16 enrolled